Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 3
1975 4
1976 4
1977 5
1978 9
1979 21
1980 27
1981 47
1982 54
1983 68
1984 75
1985 119
1986 108
1987 131
1988 123
1989 132
1990 146
1991 116
1992 148
1993 151
1994 133
1995 147
1996 141
1997 121
1998 122
1999 106
2000 111
2001 92
2002 101
2003 106
2004 125
2005 110
2006 134
2007 140
2008 144
2009 152
2010 184
2011 202
2012 207
2013 229
2014 262
2015 245
2016 263
2017 278
2018 256
2019 284
2020 263
2021 245
2022 171
2023 144
2024 222

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,276 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. O'Donnell PH, et al. J Clin Oncol. 2023 Sep 1;41(25):4107-4117. doi: 10.1200/JCO.22.02887. Epub 2023 Jun 27. J Clin Oncol. 2023. PMID: 37369081 Free PMC article. Clinical Trial.
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, Nam AR, Oh KS, Kim JM, Lee Y, Guthrie V, McCoon P, Li W, Wu S, Zhang Q, Rebelatto MC, Kim JW. Oh DY, et al. Lancet Gastroenterol Hepatol. 2022 Jun;7(6):522-532. doi: 10.1016/S2468-1253(22)00043-7. Epub 2022 Mar 9. Lancet Gastroenterol Hepatol. 2022. PMID: 35278356 Clinical Trial.
Cisplatin-Induced Kidney Injury: Delivering the Goods.
Curry JN, McCormick JA. Curry JN, et al. J Am Soc Nephrol. 2022 Feb;33(2):255-256. doi: 10.1681/ASN.2021121591. J Am Soc Nephrol. 2022. PMID: 35101994 Free PMC article. No abstract available.
Neurotoxic side-effects of cisplatin.
Harmers FP, Gispen WH, Neijt JP. Harmers FP, et al. Eur J Cancer. 1991;27(3):372-6. doi: 10.1016/0277-5379(91)90549-s. Eur J Cancer. 1991. PMID: 1827334 Review. No abstract available.
Cisplatin-induced nephrotoxicity.
Meijer S, Sleijfer DT, Mulder NH, Donker AJ. Meijer S, et al. Neth J Med. 1982;25(8):262-9. Neth J Med. 1982. PMID: 6755283 Review. No abstract available.
6,276 results